

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (withdrawn): An agent for the prevention and/or treatment of Alzheimer's disease containing c-Abl and/or p19^{ARF} as an active ingredient(s).

2. (canceled).

3. (currently amended): A method for screening method wherein a drug which inhibits the interaction between AICD (APP intracellular C terminal domains) and p53 in neurons is selected a compound for development of a drug for the ~~prevention and/or treatment of~~ Alzheimer's disease, said ~~screening method~~ comprising:

~~expressing AICD and p53 in the presence of cisplatin to form an AICD/p53 complex in neurons;~~

~~culturing the neurons together with a candidate drug;~~

(a) culturing a neuron expressing APP intracellular C terminal domains (AICD) and p53 in a culture medium that is supplemented with cisplatin, wherein said neuron is cultured (i) in the presence of a candidate compound and (ii) in the absence of the candidate compound, respectively, to give cultured neurons;

(b) homogenizing the cultured neurons to form a cell lysate[[:]],

(c) bringing contacting the cell lysate in contact with a first antibody selected from an anti-AICD antibody and an anti-p53 antibody, to form, to form a first immune complex of AICD or p53 with the first antibody, and to form a second immune complex of the AICD/p53 complex

~~with the first antibody; an AICD/p53/first antibody immune complex, wherein said first antibody is selected from the group consisting of an anti-AICD antibody and an anti-p53 antibody,~~

~~bringing the first and second immune complexes in contact with a second antibody selected from an anti-AICD antibody and an anti-p53 antibody and different from the first antibody, to form a third immune complex of the second immune complex with the second antibody;~~

~~(d) detecting and quantifying the third AICD/p53/first antibody immune complex using an immunological technique; and from step (c),~~

~~(e) comparing the amount of the AICD/p53/first antibody immune complex formed in the absence of the candidate compound with the amount of the AICD/p53/first antibody immune complex formed in the presence of the candidate compound, and~~

~~(f) selecting the candidate drug for development of a drug for the prevention and/or treatment of Alzheimer's disease,~~

~~wherein the candidate drug is selected, if the quantity of the third immune complex is small compared to the case where the candidate drug is not contained in the culture compound that decreases the amount of the AICD/p53/first antibody immune complex compared to the amount of the AICD/p53/first antibody immune complex formed in the absence of the compound, wherein said decrease in the amount of the AICD/p53 complex is indicative of the compound inhibiting binding between AICD and p53.~~

4. (withdrawn): An agent for the prevention and/or treatment of Alzheimer's disease containing AICD as an active ingredient.

5. (withdrawn): An agent for the prevention and/or treatment of Alzheimer's disease containing a peptide which comprises the amino acid sequence set forth in SEQ ID NO: 1 or 2 of the Sequence Listing as an active ingredient.

6. (withdrawn): A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

7. (withdrawn): A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

a step of culturing neurons expressing AICD and Fe65 in which an AICD/Fe65 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Fe65 with a first antibody selected from an anti AICD antibody and an anti-Fe65 antibody, and a second immune complex which is a complex of the AICD/Fe65 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Fe65 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

8. (withdrawn): A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

9. (withdrawn): A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

a step of culturing neurons expressing AICD and Tip60 in which an AICD/Tip60 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Tip60 with a first antibody selected from an anti-AICD antibody and an anti-Tip60 antibody, and a second immune complex which is a complex of the AICD/Tip60 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Tip60 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

10. (withdrawn): A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 3.

11. (withdrawn): A drug for the prevention and/ or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 7.

12. (withdrawn): A drug for the prevention and/ or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 9.

13. (new): The method according to claim 3, wherein the step (d) is conducted by contacting the AICD/p53/first antibody immune complex with a second antibody, wherein the second antibody is selected from an anti-AICD or an anti-p53 antibody and is different from the first antibody.